Connect with us

Emerging Markets

Innovative Payment Solutions Inc (OTCMKTS: IPSI) Breaking Out Northbound as Digital Payment Provider Gets Approved by VISA and Launches IPSIPay App in App Store

Published

12 months ago

on

Innovative Payment Solutions Inc (OTCMKTS: IPSI) is a low float digital payment solution targeting the $100 billion payment remittance market that is quickly climbing up the charts and getting noticed by investors. Currently trading at a $12 million market valuation the stock ran to $0.36 in February 2021 with virtually the same share structure as it has today. IPSI is an SEC filer and fully reporting OTCQB with little debt and $3.6 million in the treasury. During early May the stock dropped below the $0.01 mark and there was over 10 million sold there as the seller that had driven the stock down from its 2021 highs sold the rest of their position. Since than IPSI has bene moving steadily northbound as there are buyers and no sellers. As volume has picked up substantially in recent days the stock is starting to see some explosive moves to the upside running 43% on Friday alone, a day when the DOW was down over 880 points. 

While the Company has been slow on press recently in April, they announced the second-phase launch of the IPSIPay App following approval from VISA® for use of its debit card services as part of IPSIPay. Following the initial launch of IPSIPay in December 2021, the availability of VISA debit card capability as part of IPSIPay enhances IPSIPay’s positioning as an attractive mobile banking solution for IPSI’s initial target market — the large and growing unbanked, under banked and money remittance market worth $50 billion just between US and Mexico. The IPSIPay app provides a cheaper, faster, secure and more convenient. Users can use the App to send wallet to wallet transactions and load money to VISA Debit cards, enabling customers to access funds through ATMs as well the hundreds of thousands of businesses that accept VISA throughout Mexico. Currently, sending money with the App is free to both the sender and the recipient, making it a cost-effective solution for a population of people that generally have limited access to banking services. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!


Innovative Payment Solutions Inc (OTCMKTS: IPSI) operating out of Carmel by the Sea, California is a fintech provider of digital payment solutions and services to businesses and consumers. The Company is focused on operating and developing “e-wallets” that enable consumers to deposit cash, convert it into a digital form, and remit the funds to Mexico and other countries quickly and securely. IPSI first e-wallet, the Beyond Wallet, is currently operational. The Company’s flagship e-wallet, IPSIPay, was soft launched in December 2021. 

In January IPSI launched the IPSIPay App (find it here in app store) representing a significant step in the Company’s strategy to establish a dominant foothold in the biggest remittance markets around the world. The Company’s IPSIPay App provides a cost-effective way for users to remit money to Mexico, which, according to wral.com, is the third largest remittance recipient in the world, and represents annual remittances of over $50 billion. In addition to its functionality to send and receive funds, the IPSIPay App also acts as a digital wallet, enabling users to perform many banking related functions, including the ability to use a VISA debit card to execute financial transactions. The App also enables users to invest in crypto currencies, gold, and silver.  

In addition to Mexico, IPSI is also targeting India and the Philippines, representing three of the top four remittance recipients in the world. The IPSIPay App, in addition to the ability to make remittance payments, provides various other valuable services for the unbanked and underbanked, offering a low-cost solution that enables them to have access to many digital payment services conducted through their phone.   Relative to alternatives in the marketplace, the IPSIPay App provides remittance and bank-like services at a discount, providing a viable alternative with lower costs and greater functionality. The lower costs associated with the IPSIPay App are aligned with the United Nations’ current mandate to reduce remittance costs, whose objectives are to help migrant workers around the world. 

To Find out the inside Scoop on IPSI Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

IPSI

IPSI has engaged Response Media to execute a digital marketing campaign and maximize the awareness of the IPSIPay platform. The Company is confident that, as prospective users better understand the capabilities and the attractive price point of the IPSIPay App, IPSI will see a strong uptake in the number of active users. 

On April 4, IPSI announced the second-phase launch of its IPSIPay App following approval from VISA® for use of its debit card services as part of IPSIPay. Following the initial launch of IPSIPay in December 2021, the availability of VISA debit card capability as part of IPSIPay enhances IPSIPay’s positioning as an attractive mobile banking solution for IPSI’s initial target market — the large and growing unbanked, under banked and money remittance market. 

The new IPSIPay VISA debit cards may be obtained via the IPSIPay App, enabling users to conduct transactions anywhere VISA is accepted globally. The VISA debit card is loaded using the IPSIPay App, providing users the ability to withdraw cash with minimal fees from their digital wallet using the VISA debit card in ATM machines. The IPSIPay VISA debit card also gives customers access to their money from a large merchant network around the world, providing the ability to make everyday purchases anywhere that accepts VISA cards. Simultaneously, the cards provide users with a bank account via Metropolitan Bank, thereby enabling a path for users to potentially establish or enhance their credit. 

This second phase launch of the IPSIPay app also features increased functionality, including the ability for users to make cash deposits into their IPSIPay wallets at branches of Chase, Bank of America and Wells Fargo, which immediately becomes available for use in their digital wallet on the IPSIPay app. This increased functionality also supports all current IPSIPay features, such as wallet-to-wallet cashless transactions – including over borders (including from the U.S. to Mexico). 

The IPSIPay VISA debit card provides a means for those accustomed to relying on cash the ability to live in the cashless economy that has emerged, providing a convenient, efficient, and cost-effective way for the unbanked and underbanked to move money at rates significantly lower than traditional methods. Fees associated with accessing money through ATMs are minimal, and there is no cost for users to move funds from wallet to wallet or for shopping directly with their wallet, providing IPSIPay users with flexibility in remitting money across borders. 

The card provides significant benefits to IPSIPay App users, ultimately making it easier and cheaper to transfer money to and from anywhere around the world. The VISA debit card also provides users the ability to withdraw funds from their IPSIPay digital wallet, providing much more flexibility for users in accessing money that is on their IPSIPay App and giving users access to a large network of ATMs. 

IPSI CEO William Corbett said “We believe that while these benefits will be game-changing for our users and creates the potential to add millions of people and dollars into the cashless economy, it is just the beginning. We look forward to updating our shareholders on future promising developments for IPSI very soon.”  

 For More on IPSI Subscribe Right Now!

Currently trading at a $12 million market valuation IPSI has 367,901,679 shares outstanding, 90,036,969 of which are restricted leaving 277,864,710 free trading IPSI shares. The Company is well funded with $3.6 million in the treasury and they don’t dilute the stock. IPSI OS has not changed since August of 2021 and is virtually the same share structure IPSI had in February 2021 when the stock ran to $0.36 per share representing a $100 million plus valuation. HMBL a Company in the similar business with a significantly less well-developed product traded at a $1 billion market valuation at one point. IPSI is initially targeting southern California and then expanding to other states including Texas and Florida that have high immigrant populations. IPSI’s initial target market — the large and growing unbanked, under banked and money remittance market worth $50 billion just between US and Mexico. The Company believes it has a superior product and if they are able to capture even a very small share of the market, this represents a significant revenue opportunity for IPSI. We will be updating on IPSI when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in IPSI either long or short and we have not been compensated for this article

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Emerging Markets

Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership

Published

5 days ago

on

May 31, 2023

By

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic.

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic. The London Clinic is UK’s most renowned independent, private hospital, established 1932 with their Spine Clinic being the first specialist spinal unit based in England back in 1997.

“With a focus on providing the very best healthcare outcomes, The London Clinic is an ideal customer for Aclarion as the company works to deliver the Nociscan solution to physicians and patients around the world,” said John Sutcliffe MD, Neurosurgeon and Founder of London Spine Clinic. “The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options. Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis.”

More on Nociscan Technology

Aclarion, Inc.’s Nociscan Technology is an innovative medical solution that aims to revolutionize the diagnosis of disc-related conditions. They leverage biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain.

What’s exciting is its advantages over the current standard of care. It offers a non-invasive approach, ensuring patient comfort and safety. Given it’s non-invasive, that also means 0 pain with 0 radiation (typically associated with traditional discography). The best part is it can seamlessly integrate into standard lumbar MRI protocols, making it a convenient and efficient option for healthcare providers. 

To Discover the Inside Scoop on ACON, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The procedure takes approximately 25-45 minutes, thoroughly evaluating spinal discs without compromising accuracy. Additionally, Nociscan technology offers significant cost savings, with a list price of $1,450, making it an affordable alternative to traditional discograms. Overall, Aclarion, Inc.’s technological advances represent a significant push forward in disc-related diagnostic techniques, prioritizing patient well-being, convenience, and affordability.

https://twitter.com/TigerLineTrades/status/1663527784143093762?s=20

Nociscan Study

They also recently completed a study that spanned two years and involved 78 patients at a single site. The success rate soared to an impressive 85% for patients whose treatment strategy aligned with the disks identified by Nociscan. This represented a remarkable 22% improvement over patients whose treatment strategy did not consider the insights provided by Nociscan.

Aclarion expressed confidence that the results of the trial demonstrate the potential of Nociscan to assist physicians in successfully treating DLBP. Dr. Matthew Gornet, orthopedic surgeon and lead author of the study, enthusiastically endorsed Nociscan, stating, “The two-year surgical outcomes of the clinical trial provide unequivocal evidence of its effectiveness, particularly with regards to the primary endpoint, the Oswestry Disability Index (ODI). I firmly believe that Nociscan has the potential to revolutionize the standard of care and accurately aid all physicians treating chronic low back pain.”

It is worth noting that although Nociscan was performed on all patients in the study, it was not part of the surgical decision-making process, as highlighted by the company.

Conclusion

The commercial agreement between Aclarion, Inc. and the prestigious London Clinic signifies a significant milestone for both parties, carrying the potential for global recognition, revenue growth, and scalability. By integrating Aclarion’s innovative Nociscan Technology, the London Clinic demonstrates its commitment to delivering cutting-edge healthcare to optimize patient well-being and enhance clinical outcomes. Furthermore, the partnership’s success holds the potential for scaling Nociscan Technology to other institutions and markets, propelling Aclarion, Inc. to become a global leader in non-invasive medical technologies while driving substantial revenue growth.

We will update you on ACON when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PIRO from Pixabay

Continue Reading

Emerging Markets

Aemetis Inc. (NASDAQ: AMTX) Pioneers Renewable Fuel Market with EPA Approval

Published

2 weeks ago

on

May 21, 2023

By

Aemetis (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the EPA.

Aemetis, Inc. (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the U.S. EPA to generate renewable identification numbers (RINs) under the federal Renewable Fuel Standard. They have six dairy biogas digesters up and running, with a seventh one scheduled to start operating in June 2023.

Aemetis plans to generate multiple sources of revenue from its renewable natural gas. They will sell the gas to replace petroleum diesel in transportation, sell California Low Carbon Fuel Standard credits to fuel blenders who need to meet carbon reduction requirements in California, sell the RINs generated under the federal Renewable Fuel Standard, and benefit from production tax credits starting in 2025 under the Inflation Reduction Act.

They have completed constructing and operating six dairy digesters, a biogas pipeline spanning over 40 miles, a central facility to upgrade biogas to renewable natural gas, and a utility pipeline interconnection unit. The renewable natural gas is injected into the utility gas system and stored underground until Aemetis Biogas obtains carbon intensity (CI) pathway approvals from the California Air Resources Board (CARB) to sell credits under the California Low Carbon Fuel Standard.

They have already completed 90 days of renewable natural gas production and data collection required for the CARB approval process. While the final pathway is under review by CARB, Aemetis can use a temporary CI pathway with a value of -150, allowing them to start generating revenue in the third quarter of 2023.

To Discover the Inside Scoop on AMTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Andy Foster, the president of Aemetis Biogas Inc., expressed excitement about the approval of Aemetis Biogas for generating D3 RINs, as it marks a significant milestone towards generating full product revenue. He emphasized that the company’s investments since 2019 have directly reduced greenhouse gas pollution, improved air quality in Central Valley communities, and created jobs. Aemetis is committed to expanding their network of dairy digesters and producing more carbon-negative renewable natural gas to replace petroleum diesel.

The dairy digesters, pipeline project, and biogas-to-RNG facility funding includes grants from the California Department of Food and Agriculture and the California Energy Commission. Aemetis also closed a $25 million long-term financing deal with Greater Commercial Lending last fall, supported by a loan guarantee from the USDA. This project financing has a low fixed interest rate for the first five years and spans over 20 years.

Aemetis has plans to file applications for an additional $100 million of loans from the USDA’s REAP loan program. These funds will support the engineering, permitting, and construction of 31 more dairies. Each loan application will be limited to a maximum of $25 million and carry a 20-year repayment term.

https://twitter.com/Theweedfarmer/status/1658946668052504576?s=20

Where could Aemetis, Inc. (NASDAQ: AMTX) be in 5 years?

The company has an ambitious Five Year Plan to generate substantial revenue and reduce air and carbon pollution. The plan projects $2.0 billion in revenues, $496 million in net income, and $682 million in adjusted EBITDA by 2027, with strong compound annual growth rates. Aemetis aims to expand its operations by producing Renewable Natural Gas (RNG), Sustainable Aviation Fuel (SAF), Renewable Diesel fuel (RD), and other low-carbon products. The plan emphasizes the positive financial impact of the Inflation Reduction Act.

The plan highlights the financial benefits of the Inflation Reduction Act, which enables the transfer of tax credits and incentives related to production, projected to improve net income by $341 million in 2027.

The plan also focuses on revenue growth in all product lines, including expanding the dairy RNG business, constructing a renewable jet/diesel plant, implementing carbon sequestration, and improving energy efficiencies. 

The company has already achieved significant milestones, such as completing biogas pipeline construction, upgrading facilities for biogas-to-RNG production, and progressing in carbon sequestration and renewable jet/diesel plant development. The company has also secured a biodiesel purchase agreement in India and made strides in constructing a solar microgrid and implementing energy-efficient measures.

We will update you on AMTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Leopold Böttcher from Pixabay

Continue Reading

Emerging Markets

GSI Technology, Inc. (NASDAQ: GSIT): Pure AI Play Transforming Semiconductor Memory Solutions for Efficient AI Processing

Published

3 weeks ago

on

May 14, 2023

By

GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12.

GSI Technology, Inc. (NASDAQ: GSIT) has witnessed a significant surge in its stock price, from $1.62 to $3.84, at the time of writing on Friday, May 12. This represents an impressive 137% increase; the volume has been off the hook. If you look at their historical chart, $GSIT had meager volume, sometimes as low as 300 shares traded in a day. If you do the math, that’s less than $500 worth of shares traded in a day – safe to say it was virtually illiquid.

So what happened, and what drove the stock to trade 50M shares with filings or news releases?

After an in-depth examination, GSI Technology, Inc. appears to have experienced a notable turning point in its market trajectory. The catalyst for this transformation was the company’s prominent feature on Fox News, triggering an exponential dissemination of information across various platforms. It is worth highlighting an intriguing phenomenon that tends to transpire in such circumstances: purchasing shares often induces a ripple effect, encouraging further buying activity.

With Fox News bringing the company into the spotlight and stimulating investor interest, a domino effect occurred among astute day traders who eagerly seized the opportunity to partake in this promising venture. Consequently, the trading volume for GSI Technology, Inc. skyrocketed to unprecedented levels, surpassing all previously recorded thresholds.

This surge in volume stands as a testament to the immense enthusiasm that enveloped the market as traders recognized the tremendous potential inherent in $GSIT. This collective enthusiasm resulted in an extraordinary demonstration of market engagement, reflecting a widespread acknowledgment of the company’s significance and the opportunities it presents.

https://twitter.com/SamanthaLaDuc/status/1657033207412293634?s=20

This development showcases the power of influential media coverage and underscores the intriguing dynamics that can arise when investor sentiment aligns with a compelling market narrative.

To Discover the Inside Scoop on GSIT, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Founded in 1995, GSI Technology Inc. has established itself as a prominent provider of semiconductor memory solutions. The company is focused on introducing new products that capitalize on its core strengths, which include radiation-hardened memory products for extreme environments and Gemini, an advanced processing unit (APU) designed to enhance performance in various artificial intelligence (AI) applications. Headquartered in Sunnyvale, California, GSI Technology operates sales offices in the Americas, Europe, and Asia.

GSI Technology is on the verge of reporting its earnings next week, and the company operates in the storage business, which supports the development of highly efficient AI chips. Traditionally, computing involves separate chips for storage and computation, necessitating frequent data exchange. This process incurs significant power consumption and presents scalability challenges.

To address these limitations, GSI Technology has developed a groundbreaking solution called In-memory processing. This innovation substantially reduces computation time from minutes to seconds, milliseconds, or even microseconds. Notably, it also significantly diminishes power consumption and overall cost of ownership. The key to this improvement lies in the massive parallel data processing offered by GSI’s technology, featuring two million-bit processors per chip compared to thousands found in standard graphic processing units (GPUs). Consequently, the system becomes more scalable, enabling efficient and accelerated AI processing.

By streamlining the computing process and integrating storage and computation on a single chip, GSI Technology aims to revolutionize AI processing. This approach offers notable benefits regarding power efficiency, computational speed, and scalability, making it an attractive solution for a wide range of AI applications.

In conclusion, GSI Technology, Inc. is poised to deliver innovative semiconductor memory solutions emphasizing AI chip development. The company aims to reduce computation time, power consumption, and total ownership cost through its In-memory processing technology while significantly improving scalability. With its upcoming earnings report, investors and industry observers will closely watch the company’s progress in the storage business and AI chip development.

We will update you on GSIT when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening with GSIT.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.